Literature DB >> 22177150

Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer.

Leonardo O Reis1, Ubirajara Ferreira, Athanase Billis, Valéria H A Cagnon, Wagner J Fávaro.   

Abstract

PURPOSE: We compared and characterized the effects of intravesical bacillus Calmette-Guérin and/or staphylococcal enterotoxin B for nonmuscle invasive bladder cancer.
MATERIALS AND METHODS: A total of 75 female Fisher 344 rats were anesthetized. Of the rats 15 received 0.3 ml saline (control) and 60 received 1.5 mg/kg MNU (N-methyl-n-nitrosourea) intravesically every other week for 6 weeks. The rats were divided into 5 groups. The MNU and control groups received 0.3 ml saline. The bacillus Calmette-Guérin group received 10(6) cfu bacillus Calmette-Guérin. The staphylococcal enterotoxin B group received 10 μg/ml staphylococcal enterotoxin B. The bacillus Calmette-Guérin plus staphylococcal enterotoxin B group received the 2 treatments simultaneously. Each group was treated intravesically for 6 weeks. At 15 weeks all bladders were collected for histopathological and immunological evaluation, and Western blot.
RESULTS: Papillary carcinoma (pTa) and high grade intraepithelial neoplasia (carcinoma in situ) were more common in the MNU group. Papillary hyperplasia was more common in the bacillus Calmette-Guérin and enterotoxin groups. Flat hyperplasia was more common in the bacillus Calmette-Guérin plus enterotoxin group. No significant toxicity was observed. The apoptosis and cellular proliferation indexes decreased in the bacillus Calmette-Guérin, enterotoxin and bacillus Calmette-Guérin plus enterotoxin groups compared to the MNU group. Intensified vascular endothelial growth factor, matrix metalloproteinase-9, Ki-67 and insulin-like growth factor receptor-1 immunoreactivity was verified in the MNU group, moderate in the bacillus Calmette-Guérin and enterotoxin groups, and weak in the bacillus Calmette-Guérin plus enterotoxin and control groups. In contrast, intense endostatin immunoreactivity was verified in the control and bacillus Calmette-Guérin plus enterotoxin groups.
CONCLUSIONS: Bacillus Calmette-Guérin and staphylococcal enterotoxin B showed similar anti-angiogenic effects. Bacillus Calmette-Guérin plus enterotoxin treatment had additional activity compared to that of monotherapy. It was more effective in restoring apoptosis and balancing cellular proliferation, and it correlated with increased endostatin, and decreased vascular endothelial growth factor, matrix metalloproteinase-9, Ki-67 and insulin-like growth factor receptor-1 reactivity.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22177150     DOI: 10.1016/j.juro.2011.10.022

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.

Authors:  Gabriela R Passos; Juliana A Camargo; Karen L Ferrari; Mário J A Saad; Amilcar C de Mattos; Leonardo O Reis
Journal:  Med Oncol       Date:  2017-12-04       Impact factor: 3.064

2.  Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.

Authors:  Patrick Vianna Garcia; Letícia Montanholi Apolinário; Petra Karla Böckelmann; Iseu da Silva Nunes; Nelson Duran; Wagner José Fávaro
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

4.  Urothelial carcinogen resistance driven by stronger Toll-like receptor 2 (TLR2) and Uroplakin III (UP III) defense mechanisms: a new model.

Authors:  Leonardo Oliveira Reis; Karen Ferrari; Marina Zamuner; Guilherme Zweig Rocha; Athanase Billis; Wagner José Fávaro
Journal:  World J Urol       Date:  2014-05-29       Impact factor: 4.226

5.  Histopathologic and molecular comparative analyses of intravesical Aurora kinase-A inhibitor Alisertib with bacillus Calmette-Guérin on precancerous lesions of bladder in a rat model.

Authors:  Kerem Teke; Hasan Yilmaz; Ali Kemal Uslubas; Gurler Akpinar; Murat Kasap; Oguz Mutlu; Demir Kursat Yildiz; Nil Guzel; Ozdal Dillioglugil
Journal:  Int Urol Nephrol       Date:  2018-06-21       Impact factor: 2.370

6.  Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF- alpha/TNFR1 pathway in vitro and in vivo.

Authors:  Tao Yang; Runlin Shi; Lei Chang; Kun Tang; Ke Chen; Gan Yu; Yuanfeng Tian; Yonglian Guo; Wei He; Xiaodong Song; Hua Xu; Zhangqun Ye
Journal:  J Exp Clin Cancer Res       Date:  2015-02-25

7.  Current animal models of bladder cancer: Awareness of translatability (Review).

Authors:  Jie Ding; Ding Xu; Chunwu Pan; Min Ye; Jian Kang; Qiang Bai; Jun Qi
Journal:  Exp Ther Med       Date:  2014-07-11       Impact factor: 2.447

Review 8.  Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.

Authors:  Bincy Anu John; Neveen Said
Journal:  Oncotarget       Date:  2017-05-09

9.  Preventive effect of intravesical ozone supplementation on n-methyl-n-nitrosourea-induced non-muscle invasive bladder cancer in male rats.

Authors:  Kerem Teke; Tayyar A Ozkan; Oguz O Cebeci; Hasan Yilmaz; Muhammed E Keles; Levend Ozkan; Meltem O Dillioglugil; Demir K Yildiz; Ozdal Dillioglugil
Journal:  Exp Anim       Date:  2017-02-22

10.  Staphylococcus aureus Enterotoxin B Down-Regulates the Expression of Transforming Growth Factor-Beta (TGF-β) Signaling Transducers in Human Glioblastoma.

Authors:  Abolfazl Akbari; Zohreh Farahnejad; Javad Akhtari; Mahdi Abastabar; Gholam Reza Mobini; Amir Seied Ali Mehbod
Journal:  Jundishapur J Microbiol       Date:  2016-03-05       Impact factor: 0.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.